Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
Ozawade
Ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA)
View on EMAWakix
Wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.1).